BACKGROUND: Venous ports are mandatory for chemotherapy in cancer patients because prolonged infusions are required. The aim of this study was to assess the safety of peripheral arm ports for chemotherapy in patients with colorectal cancer. METHODS: A peripheral venous access port was placed in the upper arm in 113 consecutive patients with metastatic colorectal cancer (MCRC). All patients received modified FOLFOX (5-fluorouracil [5-FU]/l-leucovorin [LV]/oxaliplatin [L-OHP]) 6 or FOLFIRI (5-FU/LV/irinotecan hydrochloride [CPT-11]) regimens at least once via the venous access port. All patients were followed up at least once every 2 weeks. RESULTS: Puncture of the basilic veins was successfully completed under real-time sonographic guidance or radiographic guidance in all patients. The median operative time was 30 min. The cumulative follow-up period was 29 886 catheter days (range, 9-560 days; mean, 264 days). No procedural complications, such as pneumothorax, hemothorax, arterial puncture, or cardiovascular problems, occurred in our series. A total of nine patients (8.0%) had complications. Port-site infection occurred in six patients (5.3%; 0.20 infections per 1000 catheter-days). One patient (0.9%) had an episode of ultrasound-documented deep vein thrombosis in the ipsilateral upper extremity (0.03/1000 catheter-days). Dislocation or migration of the catheter tip occurred in two patients (0.07/1000 catheter-days). A second port was placed in six patients (5.3%) after removal of the fi rst port. CONCLUSION: Peripheral arm ports can be maintained with excellent short-and long-term outcomes. Peripheral arm ports are considered to be a good alternative to central venous ports implanted in the chest in patients with MCRC.
BACKGROUND: Venous ports are mandatory for chemotherapy in cancerpatients because prolonged infusions are required. The aim of this study was to assess the safety of peripheral arm ports for chemotherapy in patients with colorectal cancer. METHODS: A peripheral venous access port was placed in the upper arm in 113 consecutive patients with metastatic colorectal cancer (MCRC). All patients received modified FOLFOX (5-fluorouracil [5-FU]/l-leucovorin [LV]/oxaliplatin [L-OHP]) 6 or FOLFIRI (5-FU/LV/irinotecan hydrochloride [CPT-11]) regimens at least once via the venous access port. All patients were followed up at least once every 2 weeks. RESULTS: Puncture of the basilic veins was successfully completed under real-time sonographic guidance or radiographic guidance in all patients. The median operative time was 30 min. The cumulative follow-up period was 29 886 catheter days (range, 9-560 days; mean, 264 days). No procedural complications, such as pneumothorax, hemothorax, arterial puncture, or cardiovascular problems, occurred in our series. A total of nine patients (8.0%) had complications. Port-site infection occurred in six patients (5.3%; 0.20 infections per 1000 catheter-days). One patient (0.9%) had an episode of ultrasound-documented deep vein thrombosis in the ipsilateral upper extremity (0.03/1000 catheter-days). Dislocation or migration of the catheter tip occurred in two patients (0.07/1000 catheter-days). A second port was placed in six patients (5.3%) after removal of the fi rst port. CONCLUSION: Peripheral arm ports can be maintained with excellent short-and long-term outcomes. Peripheral arm ports are considered to be a good alternative to central venous ports implanted in the chest in patients with MCRC.
Authors: L J Bodner; J L Nosher; K M Patel; R L Siegel; R Biswal; C E Gribbin; R Tokarz Journal: Cardiovasc Intervent Radiol Date: 2000 May-Jun Impact factor: 2.740
Authors: R Biffi; G Martinelli; S Pozzi; S Cinieri; E Cocorocchio; F Peccatori; P F Ferrucci; R Pistorio; B Andreoni Journal: Bone Marrow Transplant Date: 1999-07 Impact factor: 5.483
Authors: P C Shetty; M K Mody; D J Kastan; R P Sharma; M W Burke; C Venugopal; T H Burke Journal: J Vasc Interv Radiol Date: 1997 Nov-Dec Impact factor: 3.464
Authors: Pierre-Yves Marcy; Nicolas Magné; Pierre Castadot; Antoine Italiano; Nicolas Amoretti; Cédric Bailet; Franck Bentolila; Jean-Claude Gallard Journal: Cancer Date: 2007-11-15 Impact factor: 6.860
Authors: Moritz Wildgruber; Sebastian Borgmeyer; Bernhard Haller; Heike Jansen; Jochen Gaa; Marion Kiechle; Reinhard Meier; Johannes Ettl; Hermann Berger Journal: Eur Radiol Date: 2014-09-20 Impact factor: 5.315
Authors: E Chu; D Haller; T Cartwright; C Twelves; J Cassidy; W Sun; M W Saif; E McKenna; S Lee; H-J Schmoll Journal: Br J Cancer Date: 2014-02-18 Impact factor: 7.640